Discovery of the Oncogenic Parp1, a Target of bcr-abl and a Potential Therapeutic, in mir-181a/PPFIA1 Signaling Pathway
miR-181a is downregulated in leukemia and affects its progression, drug resistance, and prognosis. However, the exact mechanism of its targets in leukemia, particularly in chronic myelogenous leukemia (CML), has not previously been established. Here, we use a multi-omics approach to demonstrate that...
Saved in:
Main Authors: | Chunming Gu (Author), Yanjun Liu (Author), Zhao Yin (Author), Juhua Yang (Author), Guiping Huang (Author), Xuejiao Zhu (Author), Yumin Li (Author), Jia Fei (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2019-06-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPFIA1-targeting miR-181a mimic and saRNA overcome imatinib resistance in BCR-ABL1-independent chronic myeloid leukemia by suppressing leukemia stem cell regeneration
by: Rui Su, et al.
Published: (2023) -
A Novel ELISA-Based Peptide Biosensor Assay for Screening ABL1 Activity in vitro: A Challenge for Precision Therapy in BCR-ABL1 and BCR-ABL1 Like Leukemias
by: Oksana Montecchini, et al.
Published: (2021) -
Targeting BCR-ABL1-positive leukaemias: a review article
by: Steven Leak, et al.
Published: (2023) -
Molecular genetics of BCR-ABL1 negative myeloproliferative neoplasms in India
by: Nikhil Rabade, et al.
Published: (2018) -
A Novel Naphthoquinone-Coumarin Hybrid That Inhibits BCR-ABL1-STAT5 Oncogenic Pathway and Reduces Survival in Imatinib-Resistant Chronic Myelogenous Leukemia Cells
by: Patricia Martín-Rodríguez, et al.
Published: (2019)